Market Research Logo

In Vitro Diagnostic Testing Services Market Forecasts 2015 to 2019 - Global Version

“Genomics technology drives industry growth but changes the nature of diagnostic services.....”
“ This is an impressive piece of work.” Doug Buchanan, Managing Director and CEO BC Biomedical Laboratories Ltd.

Its a market that just keeps on growing.

We have data for most countries of the world and can help you work with it.

A range of dynamic trends are pushing market growth and company valuations. Trends like ......

changing demographics
emerging economies and global prosperity
biotechnology advances in genetics
pathogen evolution
climate change
globalization
automation
Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

The only report in the world that forecasts Laboratory Tests Volumes and Retail Prices rather than sales of reagents and instruments. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Each Clinical Laboratory Department. Separate forecasts for

Clinical Chemistry
Microbiology
Hematology
Anatomic Pathology
Molecular Diagnostics
In addition there are specific test type breakouts that include:

Cardiac Biomarkers
Molecular Diagnostic Oncology
Molecular Diagnostic Genetics"Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasors of the report or as a Single Country Market Report License option (see options above).

All report data is available in Excel format on request.

See the Sample Data Pages . Data summary pages are provided for the entire world and world regions permitting global and continental forecasting.

See the Table of Contents. Hundreds of pages of useful information, hard data and up to date market developments.

See the Companies Mentioned in This Report.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.. Mr. Powell’s education includes:

B.Sc. (Chemistry) University of BC

M.B.A. (Finance and Policy) University of BC

Market Research Seminar - Burke Institute

Finance for Senior Executives - Harvard Business School
A growing market. Key growth drivers. An industry protected from economic cycles. An industry driven forward by increasing global regulations and security. The future of the calibration services industry is explored with detailed market forecasts and strategic analysis. This 2015 edition of the industry standard report provides valuable information and insight. The report doesn’t just look at market size. It examines key operational principles and industry best practices provided by industry veterans. Look at acquisition and divestiture opportunities. Revise pricing and service terms. Develop new service packaging and offerings. Consider integrated marketing programs."I recommend it as a planning tool for any organization that provides calibration services."
Dr. Malcolm Smith, Board Member NACLA, Committee Chair NCSLI
24 companies are profiled in this report.
This latest version of the report includes Major Metropolitan Market Size Table 2014.
If their country is not already listed purchasors can request Inividual Country Market Size information, or other customization, without additional charge.
All the important facts are here. Industry growth rates. Geographic, instrumentation and industry breakdowns of market size. Explore the potential of the industry and gain an appreciation of the big picture for a relatively new industry that is expanding onto a global stage.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He has over 20 years experience in the calibration services industry as both a consultant and executive. Mr. Powell’s education includes:
B.Sc. (Chemistry) University of BC
M.B.A. (Finance and Policy) University of BC
Market Research Seminar - Burke Institute
Finance for Senior Executives - Harvard Business School


1. Introduction and Market Definition
1.1 Introduction
1.2 Market Definition
1.2.1 Volumes
1.2.2 Prices
1.2.3 Revenue Market Size
1.3 Methodology
1.3.1 Authors
1.3.2 Sources
1.4 U.S. Medical Market and Clinical Laboratory Testing - Perspective
1.3.1 U.S. Medicare Expenditures for Clinical Testing
2. Market Overview
2.1 Market Participants
2.1.1 Supplier/pharmaceutical
2.1.2 Independent lab specialized/esoteric
2.1.3 Independent lab national/regional
2.1.4 Independent lab analytical
2.1.5 Public National/regional lab
2.1.6 Hospital lab
2.1.7 Physician lab
2.1.8 Audit body
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT
2.4 Profiles of Key Companies
2.4.1 Quest Diagnostics
2.4.2 Laboratory Corporation of America
2.4.3 Lifelabs Medical Laboratory Services
2.4.4 ACM Medical Laboratory
2.4.5 Spectra Spectra Laboratories, Inc.
2.4.6 Bio-Reference Laboratories, Inc.
2.4.7 Signal Genetics LLC
2.4.8 CompuNet Clinical Laboratories, LLC
2.4.9 Genzyme Corporation
2.4.10 Sonic Healthcare Limited
2.4.11 Exagen Diagnostics, Inc.
2.4.12 Clongen Laboratories LLC
2.4.13 Clinical Reference Laboratory, Inc.
2.4.14 Rosetta Genomics Inc.
2.4.15 Mid America Clinical Laboratories, LLC
2.4.16 Alere Inc
2.4.17 Caris Life Sciences, Inc.
2.4.18 Psychemedics Corp.
2.4.19 Aurora Diagnostics, LLC
2.4.20 DL Reference Laboratory
2.4.21 Myriad Genetics, Inc.
2.4.22 Bioscientia Institut fuer Medizinische Diagnostik GmbH
2.4.23 Acibadem Labmed Laboratory
2.4.24 Claymon Biomnis Laboratories Ltd.
2.4.25 Biomnis (France)
2.4.26 The Doctor’s Laboratory (Sonic Healthcare U.K.)
2.4.27 Pathology Inc.
2.4.28 Gribbles Pathology
2.4.29 BP Lab
2.4.30 Adicon Clinical Laboratories, Inc.
2.4.31 Diagnósticos da América (DASA)
2.4.32 Medicus Phillipines Inc.
2.4.33 Kingmed Diagnostics
2.4.34 Ascend Clinical, LLC
2.4.35 Unilabs SA
2.4.36 American Pathology Partners, Inc.
2.4.37 Centrex Clinical Laboratories, Inc.
2.4.38 Integrated Regional Laboratories, Inc.
2.4.39 Vira Cor-Ibt Laboratories
2.4.40 Clarient, Inc.
2.4.41 Genomic Health, Inc.
2.4.42 ARUP Laboratories, Inc.
2.4.43 MEDTOX Scientific, Inc.
2.4.44 Solstas Lab Partners
2.4.45 Predictive Biosciences, Inc.
2.4.46 Enzo Biochem, Inc.
2.5 National and Regional Diversity
3. Market Trends
3.1 Factors Driving Growth
3.1.1 Impact of U.S. Health Reform (PPACA) on U.S. Market
3.1.2 Understanding the Impact of Aging Population.
3.1.3 Economic growth drives health spending.
3.1.4 Point of Care Testing can increase demand
3.1.5 Wellness concerns create growth
3.1.6 Esoteric Testing Moving Mainstream
3.1.7 Genetic Based Testing Creates New Department and New Discipline
3.2 Factors Limiting Growth
3.2.1 Lower costs trend to continue
3.2.2 Economic or population contraction.
3.2.3 Testing usage analysis curtailing growth.
3.2.4 Wellness has a downside
3.2.5 Test Displacement Impacts Important
3.2.6 Point of Care Testing
3.3 Automation
3.3.1 Stranded LIMS Investment
3.3.2 Software as a Service
3.3.3 Physician Office and Access Systems
3.4 Environment and Evolution
3.5 Diagnostic Technology Development
3.5.1 Next Generation Sequencing Fuels a Revolution
3.5.2 Impact of NGS on pricing
3.5.3 POCT/Self Testing Disruptive Force
3.5.4 Pharmacogenomics Blurs Diagnosis and Treatment
3.5.5 CGES Testing, A Brave New World
3.5.6 Molecular Diagnostics Technologies At The Forefront of Growth
3.5.7 Biochips/Giant magneto resistance based assay
4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments
4.1 Recent Developments – Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
4.2 Roche acquires in vitro diagnostics company GeneWEAVE
4.3 T2 Biosystems' Q2 Net Loss Widens as It Expands Commercialization Efforts
4.4 Roche to Acquire Enzyme Engineering Firm Kapa Biosystems
4.5 Genalyte Raises $44M in Series C Financing
4.6 Nanosphere Q2 Revenues Shoot Up 76 Percent
4.7 OvaGene, Etta to Develop Multiplexed MDx Tests for Gynecologic Cancer
4.8 R-Biopharm, Apogenix to Develop CDx for Cancer Drug
4.47 OpGen Files for IPO for up to $37M
4.48 Transgenomic Closes Public Offering of Stock, Warrants
4.49 Qiagen Discloses $114.2M Price Tag for Enyzmatics Acquisition
4.50 Laboratory Corporation of America Holdings Full Year Results
4.51 GenomeDx Biosciences Implements Clarity LIMS
4.52 Merck Serono and Sysmex Inostics Announce Testing Center
4.53 Lifecode Receives CAP Accreditation, Discloses Funding
4..54 Baylor College of Medicin, Miraca Holdings finalize joint venture.
4.55 23andMe Gets FDA Clearance to Market Bloom Syndrome Carrier Test
4.56 LabCorp to Buy Covance for $6.1 Billion to Add Drug R&D
4.57 Trinity Biotech Revenues Grow by 15%
4.58 Google’s Latest Healthcare Initiative
4.59 Trinity Biotech Announces US Clinical Trials
4.60 Agena Bioscience Launches Smaller Format MassArray
4.61 QuantRx® Biomedical Provides Update on Technological Progress
4.62 The Journal of Molecular Diagnostics Publishes Special Article
4.63 Caprion Licenses Indi's Xpresys as Part of Larger Clinical Push
4.64 MDxHealth's ConfirmMDx Genes Detect Prostate Cancer
4.65 Atossa Genetics Announces That Its Subsidiary The National Reference Laboratory for Breast Health Has Received Accreditation
4.66 Nuclea Bio Plans Entry into Clinical Proteomics
4.67 Personal Genome Diagnostics Aims for FDA Clearance
4.68 Enzo Biochem Announces New Molecular Platform
4.69 Multiplicom, Premaitha Develop CE-IVDs
4.70 Regulating the Next Generation of Genetic Testing
4.71 BioReference Laboratories, Inc. Launches an Advanced Tumor Sequencing Program
4.72 Cytogenetics Become First Certified Lab to Offer Microarray Testing
4.73 Results Support Clinical Validity of Quantose IGT(TM) Diabetes Test
4.74 Accelerate Diagnostics' 2014 Revenues Rise Sharply
4.75 NanoString's Q4 Revenues Jump 54 Percent
4.76 New Aussie Firm Life Letters Launches Carrier, PGx Testing for Consumers
4.77 HTG Molecular Reports 50 Percent Increase in 2014 Revenues
4.79 LabCorp Posts 5 Percent Revenue Growth
4.80 Genomic Vision, Quest Extend Pact for Molecular Combing Technology
4.81 ACT Genomics Raises $8M in Private Funding Round
4.82 NGS-based Cancer MDx Firm Lifecode Raises $20.5M, Receives CAP Accreditation
4.83 Invitae Goes Public with $101.6M Offering
4.84 Quidel Q4 Revenues Grow 27 Percent on Infectious Disease Sales
4.85 Rosetta Signs Deal to Promote Precipio's Cancer Diagnostics
4.86 Premaitha Iona NIPT Lands CE Mark
4.87 Sera Increases Series B Round to $25M with $5M from Gates Foundation
4.88 T2 Biosystems Inks $8.5M Lyme Disease Dx Deal with Canon US Life Sciences
4.89 Invitae Amends IPO Filing Targeting up to $92.3M
4.90 Biofortuna Closes $2.2M Funding Round
4.91 Roche MDx Sales Help Drive 2014 Diagnostics Revenues up 3 Percent
4.92 AltheaDx Increases Target Amount on Proposed IPO to $74.3M
4.93 BioMerieux 2014 Revenues Increase 7 Percent
4.94 Cypher Genomics and Sequenom Announce Development Agreement
4.95 Abcam to Acquire Firefly BioWorks for $28M
4.96 PerkinElmer Opens Medical Laboratory in China
4.97 Human Longevity, Genentech Ink Deal to Sequence Thousands of Genomes
4.98 GenMark Projects 52 Percent Growth in Q4 Revenues
4.99 Amarantus Acquires DioGenix for up to $10.9M
4.100 Roche to Invest up to $1.2B in Foundation Medicine, Take Majority Stake
4.101 DiaCarta Raises $8M in Series A Round
4.102 Epic Sciences' Cancer Dx Laboratory Receives CLIA Certification
4.103 Adaptive Biotechnologies Acquires Sequenta
4.104 Aegis Sciences Acquires MDx Firm Diagnovus
4.105 Interleukin Genetics Secures $10M in Financing
4.106 Premaitha NIPT Test Receives ISO Certification
4.107 HTG Molecular Diagnostics Files for IPO of up to $60M
4.108 CardioDx Raises $35M
4.109 MolecularMD Receives CAP Accreditation
4.110 14M Genomics Secures £12.5M Equity Financing for Oncology Dx
4.111 Protagen Closes First Part of Financing Round
4.112 Glyconics Inks Exclusive Licensing Deal
4.113 Great Basin Scientific Begins Trial for Staph Assay
4.114 Response Genetics Receives NYS Approval for Cancer Test
4.115 Claritas Genomics Adopts NextCode Health Platform to Interpret NGS Tests
4.116 FDA Clears Quidel's MDx for Bordetella Pertussis
4.117 FDA Clears Additional Flu Strains for Focus' MDx Assay
4.118 Novacyt Raises $3.8M in Private Equity
4.119 Good Start Genetics Licenses PGS Technology from Johns Hopkins
4.120 Metamark's Cambridge Lab Receives CAP Accreditation
4.121 Australia's VCGS Inks Deal with Illumina to Develop NIPT
4.122 LabCorp Acquires Bode Technology
4.123 Personalized Medicine Firm Newtopia Garners Investment from Bloom Burton
4.124 Roche to Acquire Ariosa Diagnostics
4.125 CMS Issues Final Payment Decision
4.126 MDx Firm Curetis Closes $18M Series B Extension
4.127 Australia's Proteomics International Laboratories Launches A$6M IPO
4.128 Australian MDx Firm Genetic Signatures Eyes IPO for up to A$15M
4.129 N-of-One to Support Oncology Testing at BloodCenter of Wisconsin
4.130 Signal Genetics Q3 Revenues Move up 32 Percent
4.131 Sequenta, Illumina Strike IVD Deal
4.132 Veracyte Q3 Revenues Spike 75 Percent
4.133 Great Basin's Q3 Revenues Jump 83 Percent
4.134 Response Genetics Q3 Revenues Improve 9 Percent
4.135 Roche Gets FDA Clearance for Strep A MDx Test
4.136 GeneNews Q3 Revenues up Sharply
4.138 Epigenomics Q3 Revenues Grow 7 Percent
4.139 CareDx Q3 Revenues up 16 Percent
4.140 Exagen Records Sharp Increase in Revenues for First Nine Months of 2014
4.141 CollabRx, Cartagenia Partner to Provide Cancer Testing
4.142 Prostate Management Dx Closes $1.1M Series A Financing
4.143 Roka Bioscience Posts Jump in Q3 Revenues
4.144 Pacific Biosciences Files $150M Shelf Registration
4.155 Foundation Medicine Doubles Q3 Revenues
4.156 Nanosphere Q3 Revenues Climb 54 Percent
4.157 Hologic Fiscal Q4 Revenues Increase 6 Percent
4.158 MDxHealth Raises $15.4 Million in Private Stock Offering
4.159 Genomic Health Reports 5 Percent Revenue Growth in Third Quarter
4.160 NanoString Posts 47 Percent Q3 Revenue Growth
4.161 AstraZeneca's MedImmune Acquiring Definiens for at Least $150M
4.162 PDI Acquires MDx Firm RedPath Integrated Pathology
4.163 GenMark Q3 Revenues Rise 37 Percent
5. Country Market Sizes – North America
5.1 United States of America
5.1.1 Clinical Chemistry – Volumes, Prices, Revenues
5.1.2 Microbiology – Volumes, Prices, Revenues
5.1.3 Hematology – Volumes, Prices, Revenues
5.1.4 Anatomic Pathology – Volumes, Prices, Revenues
5.1.5 Molecular Diagnostics – Volumes, Prices, Revenues
5.1.6 All Clinical Testing – Volumes, Prices, Revenues
5.2 Canada
5.2.1 Clinical Chemistry – Volumes, Prices, Revenues
5.2.2 Microbiology – Volumes, Prices, Revenues
5.2.3 Hematology – Volumes, Prices, Revenues
5.2.4 Anatomic Pathology – Volumes, Prices, Revenues
5.2.5 Molecular Diagnostics – Volumes, Prices, Revenues
5.2.6 All Clinical Testing – Volumes, Prices, Revenues
6. Country Markets – Europe
6.1 France
6.1.1 Clinical Chemistry – Volumes, Prices, Revenues
6.1.2 Microbiology – Volumes, Prices, Revenues
6.1.3 Hematology – Volumes, Prices, Revenues
6.1.4 Anatomic Pathology – Volumes, Prices, Revenues
6.1.5 Molecular Diagnostics – Volumes, Prices, Revenues
6.1.6 All Clinical Testing – Volumes, Prices, Revenues
6.2 Germany
6.2.1 Clinical Chemistry – Volumes, Prices, Revenues
6.2.2 Microbiology – Volumes, Prices, Revenues
6.2.3 Hematology – Volumes, Prices, Revenues
6.2.4 Anatomic Pathology – Volumes, Prices, Revenues
6.2.5 Molecular Diagnostics – Volumes, Prices, Revenues
6.2.6 All Clinical Testing – Volumes, Prices, Revenues
6.3 United Kingdom
6.3.1 Clinical Chemistry – Volumes, Prices, Revenues
6.3.2 Microbiology – Volumes, Prices, Revenues
6.3.3 Hematology – Volumes, Prices, Revenues
6.3.4 Anatomic Pathology – Volumes, Prices, Revenues
6.3.5 Molecular Diagnostics – Volumes, Prices, Revenues
6.3.6 All Clinical Testing – Volumes, Prices, Revenues
6.4 Spain
6.4.1 Clinical Chemistry – Volumes, Prices, Revenues
6.4.2 Microbiology – Volumes, Prices, Revenues
6.4.3 Hematology – Volumes, Prices, Revenues
6.4.4 Anatomic Pathology – Volumes, Prices, Revenues
6.4.5 Molecular Diagnostics – Volumes, Prices, Revenues
6.4.6 All Clinical Testing – Volumes, Prices, Revenues
6.5 Italy
6.5.1 Clinical Chemistry – Volumes, Prices, Revenues
6.5.2 Microbiology – Volumes, Prices, Revenues
6.5.3 Hematology – Volumes, Prices, Revenues
6.5.4 Anatomic Pathology – Volumes, Prices, Revenues
6.5.5 Molecular Diagnostics – Volumes, Prices, Revenues
6.5.6 All Clinical Testing – Volumes, Prices, Revenues
6.6 Russia
6.6.1 Clinical Chemistry – Volumes, Prices, Revenues
6.6.2 Microbiology – Volumes, Prices, Revenues
6.6.3 Hematology – Volumes, Prices, Revenues
6.6.4 Anatomic Pathology – Volumes, Prices, Revenues
6.6.5 Molecular Diagnostics – Volumes, Prices, Revenues
6.6.6 All Clinical Testing – Volumes, Prices, Revenues
6.7 Remainder of Europe and Former Soviet Union
6.7.1 Clinical Chemistry – Volumes, Prices, Revenues
6.7.2 Microbiology – Volumes, Prices, Revenues
6.7.3 Hematology – Volumes, Prices, Revenues
6.7.4 Anatomic Pathology – Volumes, Prices, Revenues
6.7.5 Molecular Diagnostics – Volumes, Prices, Revenues
6.7.6 All Clinical Testing – Volumes, Prices, Revenues
7. Country Markets – Asia Pacific
7.1 China
7.1.1 Clinical Chemistry – Volumes, Prices, Revenues
7.1.2 Microbiology – Volumes, Prices, Revenues
7.1.3 Hematology – Volumes, Prices, Revenues
7.1.4 Anatomic Pathology – Volumes, Prices, Revenues
7.1.5 Molecular Diagnostics – Volumes, Prices, Revenues
7.1.6 All Clinical Testing – Volumes, Prices, Revenues
7.2 Japan
7.2.1 Clinical Chemistry – Volumes, Prices, Revenues
7.2.2 Microbiology – Volumes, Prices, Revenues
7.2.3 Hematology – Volumes, Prices, Revenues
7.2.4 Anatomic Pathology – Volumes, Prices, Revenues
7.2.5 Molecular Diagnostics – Volumes, Prices, Revenues
7.2.6 All Clinical Testing – Volumes, Prices, Revenues
7.3 South Korea
7.3.1 Clinical Chemistry – Volumes, Prices, Revenues
7.3.2 Microbiology – Volumes, Prices, Revenues
7.3.3 Hematology – Volumes, Prices, Revenues
7.3.4 Anatomic Pathology – Volumes, Prices, Revenues
7.3.5 Molecular Diagnostics – Volumes, Prices, Revenues
7.3.6 All Clinical Testing – Volumes, Prices, Revenues
7.4 India
7.4.1 Clinical Chemistry – Volumes, Prices, Revenues
7.4.2 Microbiology – Volumes, Prices, Revenues
5.1.3 Hematology – Volumes, Prices, Revenues
7.4.4 Anatomic Pathology – Volumes, Prices, Revenues
7.4.5 Molecular Diagnostics – Volumes, Prices, Revenues
7.4.6 All Clinical Testing – Volumes, Prices, Revenues
7.5 Australia
7.5.1 Clinical Chemistry – Volumes, Prices, Revenues
7.5.2 Microbiology – Volumes, Prices, Revenues
7.5.3 Hematology – Volumes, Prices, Revenues
7.5.4 Anatomic Pathology – Volumes, Prices, Revenues
7.5.5 Molecular Diagnostics – Volumes, Prices, Revenues
7.5.6 All Clinical Testing – Volumes, Prices, Revenues
7.6 Rest of Asia Pacific
7.6.1 Clinical Chemistry – Volumes, Prices, Revenues
7.6.2 Microbiology – Volumes, Prices, Revenues
7.6.3 Hematology – Volumes, Prices, Revenues
7.6.4 Anatomic Pathology – Volumes, Prices, Revenues
7.6.5 Molecular Diagnostics – Volumes, Prices, Revenues
7.6.6 All Clinical Testing – Volumes, Prices, Revenues
8. Country Markets – Latin America, Africa & The Middle East
8.1 Brazil
8.1.1 Clinical Chemistry – Volumes, Prices, Revenues
8.1.2 Microbiology – Volumes, Prices, Revenues
8.1.3 Hematology – Volumes, Prices, Revenues
8.1.4 Anatomic Pathology – Volumes, Prices, Revenues
8.1.5 Molecular Diagnostics – Volumes, Prices, Revenues
8.1.6 All Clinical Testing – Volumes, Prices, Revenues
8.2 Mexico
8.2.1 Clinical Chemistry – Volumes, Prices, Revenues
8.2.2 Microbiology – Volumes, Prices, Revenues
8.2.3 Hematology – Volumes, Prices, Revenues
8.2.4 Anatomic Pathology – Volumes, Prices, Revenues
8.2.5 Molecular Diagnostics – Volumes, Prices, Revenues
8.2.6 All Clinical Testing – Volumes, Prices, Revenues
8.3 Rest of Latin America
8.3.1 Clinical Chemistry – Volumes, Prices, Revenues
8.3.2 Microbiology – Volumes, Prices, Revenues
8.3.3 Hematology – Volumes, Prices, Revenues
8.3.4 Anatomic Pathology – Volumes, Prices, Revenues
8.3.5 Molecular Diagnostics – Volumes, Prices, Revenues
8.3.6 All Clinical Testing – Volumes, Prices, Revenues
8.4 Africa & The Middle East
8.4.1 Clinical Chemistry – Volumes, Prices, Revenues
8.4.2 Microbiology – Volumes, Prices, Revenues
8.4.3 Hematology – Volumes, Prices, Revenues
8.4.4 Anatomic Pathology – Volumes, Prices, Revenues
8.4.5 Molecular Diagnostics – Volumes, Prices, Revenues
8.4.6 All Clinical Testing – Volumes, Prices, Revenues
9. Global Market Summary
9.1 Global Market
9.1.1 Clinical Chemistry – Volumes, Prices, Revenues
9.1.2 Microbiology – Volumes, Prices, Revenues
9.1.3 Hematology – Volumes, Prices, Revenues
9.1.4 Anatomic Pathology – Volumes, Prices, Revenues
9.1.5 Molecular Diagnostics – Volumes, Prices, Revenues
9.1.6 All Clinical Testing – Volumes, Prices, Revenues
10. The Future of the Clinical Laboratory
Appendices
I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule – National Limit
and Midpoint
Table of Tables
Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
Table 2 Market Players by Type
Table 3 Clinical Laboratory Departments and Segments
Table 4 Laboratory Management Focus – Different Approaches
Table 5 Key Segmentation Variables Going Forward
Table 6 Factors Affecting Local Clinical Testing Demand
Table 7 Seven Factors Driving Growth
Table 8 Six Factors Limiting Growth
Table 9 Key Diagnostic Laboratory Technology Trends
Table 10 Next Generation Sequencing Technologies – Speed and Cost
Table 11 Key Point of Care Testing Uses
Table 12 Clinical Application Areas for Molecular Diagnostics
Table 13 USA Clinical Chemistry - Volume Price and Revenue Forecast
Table 14 USA Microbiology - Volume Price and Revenue Forecast
Table 15 USA Hematology - Volume Price and Revenue Forecast
Table 16 USA Anatomic Pathology - Volume Price and Revenue Forecast
Table 17 USA Molecular Diagnostics - Volume Price and Revenue Forecast
Table 18 USA All Clinical Testing - Volume Price and Revenue Forecast
Table 19 Canada Clinical Chemistry - Volume Price and Revenue Forecast
Table 20 Canada Microbiology - Volume Price and Revenue Forecast
Table 21 Canada Hematology - Volume Price and Revenue Forecast
Table 22 Canada Anatomic Pathology - Volume Price and Revenue Forecast
Table 23 Canada Molecular Diagnostics - Volume Price and Revenue Forecast
Table 24 Canada All Clinical Testing - Volume Price and Revenue Forecast
Table 25 France Clinical Chemistry - Volume Price and Revenue Forecast
Table 26 France Microbiology - Volume Price and Revenue Forecast
Table 27 France Hematology - Volume Price and Revenue Forecast
Table 28 France Anatomic Pathology - Volume Price and Revenue Forecast
Table 29 France Molecular Diagnostics - Volume Price and Revenue Forecast
Table 30 France All Clinical Testing - Volume Price and Revenue Forecast
Table 31 Germany Clinical Chemistry - Volume Price and Revenue Forecast
Table 32 Germany Microbiology - Volume Price and Revenue Forecast
Table 33 Germany Hematology - Volume Price and Revenue Forecast
Table 34 Germany Anatomic Pathology - Volume Price and Revenue Forecast
Table 35 Germany Molecular Diagnostics - Volume Price and Revenue Forecast
Table 36 Germany All Clinical Testing - Volume Price and Revenue Forecast
Table 37 U.K. Clinical Chemistry - Volume Price and Revenue Forecast
Table 38 U.K. Microbiology - Volume Price and Revenue Forecast
Table 39 U.K. Hematology - Volume Price and Revenue Forecast
Table 40 U.K. Anatomic Pathology - Volume Price and Revenue Forecast
Table 41 U.K. Molecular Diagnostics - Volume Price and Revenue Forecast
Table 42 U.K. All Clinical Testing - Volume Price and Revenue Forecast
Table 43 Spain Clinical Chemistry - Volume Price and Revenue Forecast
Table 44 Spain Microbiology - Volume Price and Revenue Forecast
Table 45 Spain Hematology - Volume Price and Revenue Forecast
Table 46 Spain Anatomic Pathology - Volume Price and Revenue Forecast
Table 47 Spain Molecular Diagnostics - Volume Price and Revenue Forecast
Table 48 Spain All Clinical Testing - Volume Price and Revenue Forecast
Table 49 Italy Clinical Chemistry - Volume Price and Revenue Forecast
Table 50 Italy Microbiology - Volume Price and Revenue Forecast
Table 51 Italy Hematology - Volume Price and Revenue Forecast
Table 52 Italy Anatomic Pathology - Volume Price and Revenue Forecast
Table 53 Italy Molecular Diagnostics - Volume Price and Revenue Forecast
Table 54 Italy All Clinical Testing - Volume Price and Revenue Forecast
Table 55 Russia Clinical Chemistry - Volume Price and Revenue Forecast
Table 56 Russia Microbiology - Volume Price and Revenue Forecast
Table 57 Russia Hematology - Volume Price and Revenue Forecast
Table 58 Russia Anatomic Pathology - Volume Price and Revenue Forecast
Table 59 Russia Molecular Diagnostics - Volume Price and Revenue Forecast
Table 60 Russia All Clinical Testing - Volume Price and Revenue Forecast
Table 61 Rest of Europe Clinical Chemistry - Volume Price and Revenue Forecast
Table 62 Rest of Europe Microbiology - Volume Price and Revenue Forecast
Table 63 Rest of Europe Hematology - Volume Price and Revenue Forecast
Table 64 Rest of Europe Anatomic Pathology - Volume Price and Revenue Forecast
Table 65 Rest of Europe Molecular Diagnostics - Volume Price and Revenue Forecast
Table 66 Rest of Europe All Clinical Testing - Volume Price and Revenue Forecast
Table 67 China Clinical Chemistry - Volume Price and Revenue Forecast
Table 68 China Microbiology - Volume Price and Revenue Forecast
Table 69 China Hematology - Volume Price and Revenue Forecast
Table 70 China Anatomic Pathology - Volume Price and Revenue Forecast
Table 71 China Molecular Diagnostics - Volume Price and Revenue Forecast
Table 72 China All Clinical Testing - Volume Price and Revenue Forecast
Table 73 Japan Clinical Chemistry - Volume Price and Revenue Forecast
Table 74 Japan Microbiology - Volume Price and Revenue Forecast
Table 75 Japan Hematology - Volume Price and Revenue Forecast
Table 76 Japan Anatomic Pathology - Volume Price and Revenue Forecast
Table 77 Japan Molecular Diagnostics - Volume Price and Revenue Forecast
Table 78 Japan All Clinical Testing - Volume Price and Revenue Forecast
Table 79 South Korea Clinical Chemistry - Volume Price and Revenue Forecast
Table 80 South Korea Microbiology - Volume Price and Revenue Forecast
Table 81 South Korea Hematology - Volume Price and Revenue Forecast
Table 82 South Korea Anatomic Pathology - Volume Price and Revenue Forecast
Table 83 South Korea Molecular Diagnostics - Volume Price and Revenue Forecast
Table 84 South Korea All Clinical Testing - Volume Price and Revenue Forecast
Table 85 India Clinical Chemistry - Volume Price and Revenue Forecast
Table 86 India Microbiology - Volume Price and Revenue Forecast
Table 87 India Hematology - Volume Price and Revenue Forecast
Table 88 India Anatomic Pathology - Volume Price and Revenue Forecast
Table 89 India Molecular Diagnostics - Volume Price and Revenue Forecast
Table 90 India All Clinical Testing - Volume Price and Revenue Forecast
Table 91 Australia Clinical Chemistry - Volume Price and Revenue Forecast
Table 92 Australia Microbiology - Volume Price and Revenue Forecast
Table 93 Australia Hematology - Volume Price and Revenue Forecast
Table 94 Australia Anatomic Pathology - Volume Price and Revenue Forecast
Table 95 Australia Molecular Diagnostics - Volume Price and Revenue Forecast
Table 96 Australia All Clinical Testing - Volume Price and Revenue Forecast
Table 97 Rest of Asia Pacific Clinical Chemistry - Volume Price and Revenue Forecast
Table 98 Rest of Asia Pacific Microbiology - Volume Price and Revenue Forecast
Table 99 Rest of Asia Pacific Hematology - Volume Price and Revenue Forecast
Table 100 Rest of Asia Pacific Anatomic Pathology - Volume Price and Revenue Forecast
Table 101 Rest of Asia Pacific Molecular Diagnostics - Volume Price and Revenue Forecast
Table 102 Rest of Asia Pacific All Clinical Testing - Volume Price and Revenue Forecast
Table 103 Brazil Clinical Chemistry - Volume Price and Revenue Forecast
Table 104 Brazil Microbiology - Volume Price and Revenue Forecast
Table 105 Brazil Hematology - Volume Price and Revenue Forecast
Table 106 Brazil Anatomic Pathology - Volume Price and Revenue Forecast
Table 107 Brazil Molecular Diagnostics - Volume Price and Revenue Forecast
Table 108 Brazil All Clinical Testing - Volume Price and Revenue Forecast
Table 109 Mexico Clinical Chemistry - Volume Price and Revenue Forecast
Table 110 Mexico Microbiology - Volume Price and Revenue Forecast
Table 111 Mexico Hematology - Volume Price and Revenue Forecast
Table 112 Mexico Anatomic Pathology - Volume Price and Revenue Forecast
Table 113 Mexico Molecular Diagnostics - Volume Price and Revenue Forecast
Table 114 Mexico All Clinical Testing - Volume Price and Revenue Forecast
Table 115 Rest of Latin America Clinical Chemistry - Volume Price and Revenue Forecast
Table 116 Rest of Latin America Microbiology - Volume Price and Revenue Forecast
Table 117 Rest of Latin America Hematology - Volume Price and Revenue Forecast
Table 118 Rest of Latin America Anatomic Pathology - Volume Price and Revenue Forecast
Table 119 Rest of Latin America Molecular Diagnostics - Volume Price and Revenue Forecast
Table 120 Rest of Latin America All Clinical Testing - Volume Price and Revenue Forecast
Table 121 Africa & Middle East Clinical Chemistry - Volume Price and Revenue Forecast
Table 122 Africa & Middle East Microbiology - Volume Price and Revenue Forecast
Table 123 Africa & Middle East Hematology - Volume Price and Revenue Forecast
Table 124 Africa & Middle East Anatomic Pathology - Volume Price and Revenue Forecast
Table 125 Africa & Middle East Molecular Diagnostics - Volume Price and Revenue Forecast
Table 126 Africa & Middle East All Clinical Testing - Volume Price and Revenue Forecast
Table 127 Global Clinical Chemistry - Volume Price and Revenue Forecast
Table 128 Global Microbiology - Volume Price and Revenue Forecast
Table 129 Global Hematology - Volume Price and Revenue Forecast
Table 130 Global Anatomic Pathology - Volume Price and Revenue Forecast
Table 131 Global Molecular Diagnostics - Volume Price and Revenue Forecast
Table 132 Global All Clinical Testing - Volume Price and Revenue Forecast
Table 133 2015 Clinical Lab Fee Schedule
Table of Figures
Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report